Get in Touch

Find out how our superior engineering can grow your bottom line.



Discover how “turning innovation into profit” can work in your company.

U.S. FDA Approves the Dexcom G4™ PLATINUM Continuous Glucose Monitor (CGM)
Posted 10/8/2012
Egret Technologies congratulates its client Dexcom, a leader in continuous glucose monitoring, on the announcement today that the U.S. Food and Drug Administration has approved its eagerly anticipated new continuous glucose monitoring system, the Dexcom G4™ PLATINUM.

Clinical trials report up to approximately 19 percent improvement in overall accuracy for the Dexcom G4™ PLATINUM compared to the Seven Plus, and approximately a 30 percent improvement in accuracy in the hypoglycemia range (i.e., when blood glucose is less than 70mg/dl). The overall accuracy and ease of use for the Dexcom G4™ PLATINUM sets a new standard for commercially available CGMs, making the Dexcom G4™ PLATINUM the most-advanced CGM system available.

The Dexcom G4™ PLATINUM offers not only outstanding accuracy and performance, but many new capabilities, including:
  • Longest transmission range, enabling improved patient flexibility and convenience
  • A smaller, discrete profile that fits busy lifestyles
  • A first-of-its-kind color LCD display for easy viewing
  • Customizable alerts with specific tones
  • “Hypo alert” setting at 55 mg/dl that provides an increased level of safety – a feature that no other device provides.
Egret Technologies was an integral part of the G4™ PLATINUM Team with responsibility for the design of the G4™ PLATINUM CGM Wireless Transmitter.

Previous Article

All Articles (1 of 14 articles)

U.S. FDA Approves IDE for Bionic Pancreas

Read More »